Rhythm Pharmaceuticals, Inc.

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity (HO).

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CEO David Meeker sold 50,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the transaction, the chief executive officer owned 239,258 shares in the

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $97.67 and last traded at $97.0350. Approximately 54,752 shares traded hands during trading, a decline of 93% from the average session volume of 750,485 shares.

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript